Ajanta Pharma Limited · NSE:AJANTPHARM
Ajanta Pharma — Q1 FY2020 Earnings Presentation
27 slides from Ajanta Pharma's earnings presentation, Jul 31, 2019
Slide 1: Cover letter to BSE and NSE: Presentation on Results
OP ajanta pharma limited Ajanta House, T +91 22 6606 1000 Charkop, Kandivli (West), | F +9122 6606 1200 Mumbai 400 067 E info@ajantapharma.com India W www.ajantapharma.com 31% July 2019 | BSE LIMITED National Stock Exchange of India, Phiroze Jeejeebhoy Towers Exchange Plaza, 5" Floor, Plot no. Dalal
Slide 2: Investor Presentation Q1 FY 2020
INVESTOR PRESENTATION Q1 FY 2020 31st July 2019
Slide 3: Content
INDIA BUSINESS GLOBAL BUSINESS CONTENT INFRASTRUCTURE FINANCIAL HIGHLIGHTS 31st July 2019 2 of 26
Slide 4: India Business
INDIA BUSINESS 31st July 2019 3 of 26
Slide 5: India Branded Generics
India Branded Generics 15 Divisions 3,000+ MRs 270+ 1st to Market for 4 segments Building efficiency Product Basket Products Continue to Focus on 4 Therapeutic Segments Cardiology Ophthalmology Dermatology Pain Management Improved ranking with 2nd largest in India, Growth becomes reality, Jumped 2 r
Slide 6: IPM - Ranking
IPM - Ranking Mar 2005 June 2018 June 2019 Ophthalmology 28 3 2 Dermatology 98 15 14 Cardiology 38 16 15 Pain Mgmt. NA 43 41 Ajanta Pharma 88 32 31 Source: IMS MAT, June 2019 31st July 2019 5 of 26
Slide 7: Industry Growth
Industry Growth March 2016 March 2017 March 2018 March 2019 June 2019 IPM Ajanta Pharma IPM Ajanta Pharma IPM Ajanta Pharma IPM Ajanta Pharma IPM Ajanta Pharma 23% 16% 16% 16% 14% 11% 10% 9% 6% 6% IPM = Indian Pharmaceutical Market Source: IMS MAT, June 2019 31st July 2019 6 of 26
Slide 8: Segment Growth
Segment Growth Pain Pharma Market Cardiology Ophthalmology Dermatology Management IPM Ajanta Pharma IPM Ajanta Pharma IPM Ajanta Pharma IPM Ajanta Pharma IPM Ajanta Pharma 18% 18% 16% 16% 13% 12% 11% 10% 10% 10% IPM = Indian Pharmaceutical Market Source: IMS MAT, June 2019 31st July 2019 7 of 26
Slide 9: India Sales
India Sales IMS MAT June 2019 India Sales – Q1 (Rs. cr.) Ophthal 30% Cardio 42% 9% 194 Derma Pain 22% 178 6% IMS MAT June 2018 Ophthal 30% Cardio 41% Derma Pain 23% 6% Q1 FY19 Q1 FY20 31st July 2019 8 of 26
Slide 10: Global Business
GLOBAL BUSINESS 31st July 2019 9 of 26
Slide 11: Global Presence
Global Presence INDIA USA AFRICA 19 Countries REST OF ASIA 10 Countries Map not to scale, only for illustration purpose 31st July 2019 10 of 26
Slide 12: Branded Generic Business in Emerging Markets
Bra n d ed Gen eric Bu sin ess in Emerg ing M a rk ets Africa Asia 1,000 + Product Registration 400 + New Products launched in 6 Q1 FY 2020 5 14 Major Markets 7 31st July 2019 11 of 26
Slide 13: USA
USA 30 25 ~10-12 Final Approvals Under Approval Filing Target 3 in Q1 FY 2020 3 in Q1 FY 2020 Launched 3 Gaining market Continue to focus 28 Products on products during share in select on better shelf the quarter products with execution for successfully focused approach customer delight 31st July 20
Slide 14: Export Sales – Q1 (Consolidated)
Export Sales – Q1 ( C o n s o l i d a t e d ) Africa Africa Asia USA Others Branded Institution (Rs. cr.) (Rs. cr.) (Rs. cr.) (Rs. cr.) (Rs. cr.) Total Exports (Rs. cr.) 20% (3%) 67% 50% 26% 129 126 102 92 81 25% 77 404 61 54 324 2 3 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 Q1
Slide 15: Total Consolidated Sales – Q1
Total Consolidated Sales – Q1 India Exports Total Sales (Rs. cr.) (Rs. cr.) (Rs. cr.) Rs. cr. 9% 25% 19% 598 Q1 Q1 Grth 502 FY 2019 FY 2020 404 India 178 194 9% 324 Exports 324 404 25% 178 194 Total Sales 502 598 19% Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 Q1 FY19 Q1 FY20 31st July 2019 14 of 26
Slide 16: Infrastructure
I N F R A S TRU C TUR E 31st July 2019 15 of 26
Slide 17: Enabling Infrastructure
Enabling Infrastructure Formulation Manufacturing 3 facilities in Aurangabad, Maharashtra 1 facility at Dahej, Gujarat 1 facility at Guwahati, Assam New facility coming up at Pithampur, Madhya Pradesh One facility at Mauritius API Manufacturing One Facility at Waluj, Aurangabad, Maharash
Slide 18: R&D Thrust
R&D Thrust R&D Spend (Excluding Capex) 5% 6% 8% 9% 9% Q1 FY 2020 185 176 Rs. 40 cr. (7%) 153 106 Q1 FY 2019 70 Rs. 41 cr. (8%) FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 31st July 2019 17 of 26
Slide 19: Financial Highlights
F I N A N C IA L H I G HLIGHTS 31st July 2019 18 of 26
Slide 20: P&L Synopsis – Q1 FY 2020 (Consolidated)
P&L Synopsis – Q1 FY 2020 ( C o n s o l i d a t e d ) Q1 Q1 % Rs. cr. % % FY 2019 FY 2020 Growth Exports 324 63% 404 66% 25% Domestic 178 35% 194 32% 9% Other Op. Income 9 2% 14 2% 49% Income from Operations 511 612 20% EBITDA 157 31% 168 28% 7% PBT 148 29% 151 25% 2% PAT 106 21% 115 19% 8% Total Co
Slide 21: Detailed P&L – Q1 FY 2020 (Consolidated)
Detailed P&L – Q1 FY 2020 ( C o n s o l i d a t e d ) Rs. cr. Q1 FY 2019 % to IO Q1 FY 2020 % to IO Income from Operations 511 612 Other Income 8 2% 8 1% Total Income 519 620 Materials consumed 84 16% 143 23% Employee Benefit 105 21% 118 19% Finance Cost 0 0% 2 0% Depreciation 17 3% 23 4% Other Expe
Slide 22: 5 Year Track Record (Consolidated)
5 Year Track Record ( C o n s o l i d a t e d ) Consolidated Total Income (Rs. cr.) 2,500 PAT (Rs. cr.) & PAT Margin (%) 2,155 2,026 2,076 21% 24% 25% 22% 19% 2,000 1,771 1,502 600 507 1,500 469 500 416 387 1,000 400 310 300 500 200 0 100 2015 2016 2017 2018 2019 0 2015 2016 2017 2018 2019 31st July
Slide 23: 5 Year Track Record (Consolidated)
5 Year Track Record ( C o n s o l i d a t e d ) EBITDA Margin Net Margin (%) (%) 34% 35% 30% 25% 40% 34% 24% 31% 21% 22% 28% 19% 30% 20% 20% 10% 10% 0% 0% 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 RONW ROCE (%) (%) 60% 60% 50% 43% 44% 50% 40% 50% 41% 37% 40% 40% 30% 26% 23% 30% 18% 30% 20% 2
Slide 24: 5 Year Track Record (Consolidated)
5 Year Track Record ( C o n s o l i d a t e d ) EPS Dividend per share (Rs.) (Rs.) (FV Rs. 2/-) 58 13 60 53 14 47 44 50 12 9 35 8 10 40 8 6 30 6 20 4 10 2 0 0 0 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 Dividend Payout Book Value per share (%) (Rs.) 300 255 30% 25% 232 21% 250 19% 178 18% 20
Slide 25: 5 Year Track Record (Consolidated)
5 Year Track Record ( C o n s o l i d a t e d ) Total Debt / Equity Receivable Days (Ratio.) (Nos.) 0.09 0.10 100 83 79 81 0.07 65 0.08 80 61 0.06 60 0.04 40 0.02 0.02 0.00 20 0.00 0.00 0 2015 2016 2017 2018 2019 2015 2016 2017 2018 2019 Inventory Days Payable Days (Nos.) (Nos.) 79 80 140 123 62 70
Slide 26: Thank You
For updates and company information please visit our website: www.ajantapharma.com For specific queries, contact: Rajeev Agarwal - 022-66061377 Thank You rajeev.agarwal@ajantapharma.com Abhineet Kumar – 022-66061814 abhineet.kumar@ajantapharma.com Ajanta Pharma Limited Ajanta House, Charkop, Kandivl
Slide 27: Disclaimer
Disclaimer This presentation may include certain ‘forward looking statements’, based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materiall